Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2020-08-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
内幕信息知情人员登记管理制度
Governance Information Classification · 95% confidence The document is a detailed internal management system for insider information registration and confidentiality within a company. It outlines procedures, responsibilities, and definitions related to insider information and insider personnel. It does not contain financial statements, earnings data, or any form of financial results. It is not an announcement or a report of financial performance but rather a governance and compliance document related to insider information management. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2020-08-25 Chinese
董事、监事和高级管理人员所持本公司股份及其变动管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled 'Management System for Shares Held and Changes by Directors, Supervisors, and Senior Management of Kuaihua Pharmaceutical Group Co., Ltd.' It outlines rules and procedures for shareholding, reporting, disclosure, and trading restrictions for company insiders. It references relevant laws and stock exchange regulations, and includes sections on responsibilities and penalties. There is no indication that this is a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and compliance requirements for board members and senior management regarding share transactions. Therefore, it fits best under Governance Information (CGR). The document length and content confirm it is the policy itself, not a brief announcement or certification.
2020-08-25 Chinese
独立董事关于公司第三届董事会第二十二次会议相关事项的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent director's opinion on several specific matters related to the company's mid-year activities, including the use of raised funds, termination of certain investment projects, external guarantees, and related party fund occupation for the first half of 2020. It references a 'special report' on the use of raised funds for the 2020 half-year period and provides independent opinions on these matters. The content is focused on compliance, governance, and specific financial oversight rather than presenting comprehensive financial statements or full financial performance data. The document length is 1571 characters, which is relatively short and more consistent with a regulatory or governance-related statement rather than a full interim or annual report. It does not contain detailed financial statements or substantive financial data typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). Instead, it is an independent opinion report related to governance and compliance matters, which aligns best with the Audit Report / Information (AR) category, as it involves audit-like independent opinions on specific financial and compliance issues. Therefore, the most appropriate classification is AR (Audit Report / Information). H1 2020
2020-08-25 Chinese
融资决策制度
Capital/Financing Update Classification · 95% confidence The document is titled '融资决策制度' which translates to 'Financing Decision System' and outlines the company's internal rules and procedures for financing activities such as issuing new shares, bonds, and borrowing from financial institutions. It references relevant laws and company bylaws and details approval processes for financing decisions. The content is a governance or procedural document rather than a financial report or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a certification. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to company financing policies and decisions.
2020-08-25 Chinese
对外投资管理办法
Governance Information Classification · 95% confidence The document is titled '葵花药业集团股份有限公司 对外投资管理办法' which translates to 'Kwaihua Pharmaceutical Group Co., Ltd. External Investment Management Measures'. It is a detailed internal policy document outlining the principles, decision-making authority, responsibilities, execution control, disposal, supervision, and disclosure related to the company's external investments. The document includes references to relevant laws and regulations, internal governance, and procedures for investment management. It does not contain financial statements, earnings data, audit opinions, or any form of financial results. It is not an announcement or a brief summary but a comprehensive internal governance and procedural manual. This type of document fits best under Governance Information (CGR), as it details the company's internal rules and governance practices related to external investments.
2020-08-25 Chinese
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the rules, qualifications, duties, and procedures related to independent directors of the company 葵花药业集团股份有限公司. The content includes governance structure, legal and regulatory references, director qualifications, nomination and election processes, rights and responsibilities, and reporting obligations. There is no financial data, earnings information, or capital structure updates. The document is a governance-related policy or internal rules document. It is not an announcement, transcript, or report of financial results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (7871 characters) supports it being a full governance document rather than a brief announcement or notice.
2020-08-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.